# MV Credit

# 3

## MVIII L.P.

### **Unaudited Management Accounts**

for the period to 30 September 2021



# MV Credit

3

# CONTENTS CONTENTS

Financial Review	3
Consolidated Balance Sheet	6
Consolidated Income Statement	7
Notes to the Management Accounts	8
Appendix to the Consolidated Financial Statements	13
Individual Investment Summary	14

#### **Financial Review**

€178.3M

NAV TOTALS AT END SEPTEMBER €641.2M\*\*

CUM DISTRIBUTIONS TO SEPTEMBER\* €1,148.2M

PRINCIPAL INVESTED TO SEPTEMBER\*\*\*


#### **Portfolio Overview**

#### Repayments

During the quarter the Fund received total repayments of €54.8m, consisting of €39.7 (\$46.5m) and €15.1m (£13.1m), details of which are:

Date	Asset	Instrument	Amount
25.08.21	ADB Safegate	Second Lien	\$47m
29.09.21	Exclusive Networks	Second Lien	£13m

#### **Principal Invested**



This chart represents all investments made by the Fund since inception.

Dear Limited Partner,

#### Market Overview

Overall Q3 European Leveraged Loan volumes (€24.8bn) were down vs Q2 (€41.3bn) and Q1 (€41.2bn), as is typical for the quarter including the summer months, however 2021's year-to-date issuance exceeds the total year issuance of all historical years on record except for 2 (2007 and 2017). Noteworthy is the composition of the type of deal flow the market is seeing, with M&A-related transactions accounting for 59% of total institutional volume this year so far, compared with 41% in 2017. Subordinated loan issuance is typically correlated to new M&A volumes and by nature lumpier than the Senior-Secured space. As the Senior Loan market has seen record growth, so too has the Subordinated Loan market been very active. The latest Subordinated facilities have been agreed on a bi-lateral basis between the private lenders and the private equity owners. MV Credit have worked on a number of transactions, some of which we had already known in the market, that are expected to complete in the near future.

As Private Equity Sponsors are always conscious of the constraints set by Underwriters on Senior Debt, we expect the most compelling assets with strong cash flow generation to be the most suitable

candidates for potential additional Subordinated Debt. Valuations for these attractive businesses in competitive markets continue to be high and Private Equity Sponsors have often sought to structure Subordinated Debt instruments to be able to meet the valuation expectations. Given the competition for auction processes, we would expect to experience more activity in existing Sponsor portfolio businesses and recapitalisations. Similar to the Senior Secured market, the MV Credit team is currently working on a number of opportunities that we expect to be confirmed by year end. MV Credit continues to maintain its rigorous investment criteria and selective approach. Our pipeline of investments mainly consists of non-cyclical businesses with a high degree of revenue recurrence and visibility.

#### Updates on COVID-19:

As a result of the COVID-19 situation, the team at MV Credit released a report in May 2021 to inform investors of the status of the portfolio. This included an analysis of all the assets within the portfolio and provided an update on the previous report released in December 2020.


 $<sup>{\</sup>it *Distributions recorded in the Capital Accounts use historical rates in line with IFRS.}\\$ 

<sup>\*\*</sup> Including Qualified Distribution on 23 February 2018 of €18.6M.

<sup>\*\*\*\*</sup> Principal invested represents all investments made to date stated at historical rates. The closing book value of the asset valuation bridge is different to the principal invested in that it represents the current portfolio at period end rates.

<sup>\*\*\*\*</sup> Unilabs Second Lien PIK Notes.

#### Financial Review




#### **NAV Overview**

During the quarter the funds made one call and two distributions as follows:

Date	Туре	Asset (if applicable)	Amount
23.07.21	Capital Call	Lima add on	€2,938,824
23.07.21	Capital Distribution	IFS	€1,332,997
23.07.21	Gain Distribution	Audiotonix & IVC	€1,605,827
23.07.21	Income Distribution		£301,879
23.07.21	Gain Distribution	IVC	£3,498,121
23.07.21	Capital Distribution	ADB Safegate	\$42,806,400
22.09.21	Income Distribution		\$3,773,187

#### **NAV Movement**





#### Financial Review

#### **Fund Performance**

#### Key Performance Indicators:

#### Ratios

IRR* €'000	Unaudited Q3 2021	Unaudited Q2 2021	Unaudited Q1 2021	Unaudited Q4 2020
Gross	12.19%	12.39%	12.40%	11.90%
Net	9.33%	9.52%	9.49%	8.93%

<sup>\*</sup> Cashflows used in the calculation of the unrealised IRR are translated at WACR in line with the LPA. The Net IRR is calculated on an unrealised basis pre-carry as per EVCA guidelines.

Total Value to Paid-In (TVPI)** €′000	Unaudited Q3 2021	Unaudited Q2 2021	Unaudited Q1 2021	Unaudited Q4 2020
Gross	1.59	1.59	1.57	1.52
Net	1.47	1.47	1.46	1.41

<sup>\*\*</sup> TVPI cashflows are translated at WACR.

Distribution to Paid-In (DPI)*** €'000	Unaudited Q3 2021	Unaudited Q2 2021	Unaudited Q1 2021	Unaudited Q4 2020
Gross	1.16	1.08	0.96	0.95
Net	1.04	0.96	0.84	0.84

<sup>\*\*\*</sup> DPI cashflows are translated at WACR.


TER	1.58%	1.05%	0.39%	2.00%
Net Assets	206,605	222,728	293,380	282,537
Management Fees	2,463	1,774	863	4,577
Expenses	804	555	283	1,077
Total Expense Ratio (TER)**** €'000	Unaudited YTD 2021	Unaudited Q2 2021	Unaudited Q1 2021	Unaudited Q4 2020

<sup>\*\*\*\*</sup> TER = Total expenses + management fees/net assets

#### NAV vs. Money at Risk

€'000

Current NAV covers well the Money at Risk with a ratio of -1.97x as of 30 September 2021.



We hope that you find the information useful and we welcome any questions or comments you may have.

MV Credit
MV Credit Partners LLP

#### Consolidated Balance Sheet

As at 30 September 2021

		Unaudited	Unaudited	Unaudited	Audited
€′000	Notes	Q3 2021	Q2 2021	Q1 2021	2020
NON-CURRENT ASSETS					
Loans		183,344	239,284	279,183	268,000
ECL Loss Allowance	6	(10,385)	(9,990)	(10,757)	(10,381)
	1	172,959	229,294	268,426	257,619
Available for Sale Equity		29,034	29,002	56,357	38,758
LOAN & INVESTMENT PORTFOLIO	1	201,993	258,296	324,783	296,377
CURRENT ASSETS					
Interest and Other Receivables		1,694	1,294	753	1,322
Cash		22,719	12,515	2,486	3,504
		24,413	13,809	3,239	4,826
TOTAL ASSETS		226,406	272,105	328,022	301,203
CURRENT LIABILITIES					
Trade Creditors and Other Payables	3	(162)	(1,883)	(330)	(243)
Tax provision		141	109	121	99
Carried interest	9	(48,080)	(47,603)	(34,433)	(18,522)
		(48,101)	(49,377)	(34,642)	(18,666)
TOTAL ASSETS LESS LIABILITIES		178,305	222,728	293,380	282,537
			,		
LIMITED PARTNER CAPITAL ACCOUNTS	4	178,305	222,728	293,380	282,537

#### **Consolidated Income Statement**

For the period ended 30 September 2021

		Unaudited	Unaudited	Unaudited	Unaudited	Audited
€'000	Notes	YTD 2021	Q3 2021	Q2 2021	Q1 2021	2020
Interest Income		17,191	4,611	6,812	5,768	29,040
Fee Income		3	-	-	3	(6)
Amortization of acquisition premiums/discounts		-	-	-	-	101
TOTAL INCOME		17,194	4,611	6,812	5,771	29,135
Foreign Exchange Movement	11	6,335	873	(2,626)	8,088	(15,912)
Other Partnership Expenses		(804)	(249)	(272)	(283)	(1,072)
Carried Interest	9	(29,558)	(477)	(13,170)	(15,911)	25,636
		(24,027)	147	(16,068)	(8,106)	8,652
ECL Loss Allowance		29	(396)	754	(329)	(2,160)
Unrealised gain/(loss) on investments	5	(5,386)	32	(22,509)	17,091	(7,367)
Realised gain/(loss) on investments	5	19,922	(4,310)	24,232	-	(30,222)
Profit/(loss) before tax		7,732	84	(6,779)	14,427	(1,962)
Taxation	7	(43)	(20)	(12)	(11)	(5)
PROFIT AND LOSS		7,689	64	(6,791)	14,416	(1,967)

# Notes to the Management Accounts For the period ended 30 September 2021

#### 1. Asset Summary

Investment   (source coy)   (sourc			А	В	С	D	E = C-D	F	G*	Н	I = B-D+H		
Part					6	501.1		501.1					
Accountor 10/12/2015 10,000 8,661 18,661 (15) 18,646 (15) 18,646 - 8,646 3.22% 11.5   Lima 11/08/2017 40,000 19,305 593,05 (92) 59,213 (92) 59,212 - 19,213 13,05% 11.5   Pronovias 03/10/2017 20,000 1,032 21,032 (8,703) 12,329 (8,703) 12,329 (8,703) 12,329 (8,703) 12,329 (8,703) 12,329 (9,703) 12,329 (9,703) 12,329 (1,70			at Cost		and PIK	Allowance	Value	Allowance	Portfolio	received ITD	Creation		MoM (Excl. ECL)
Lima 11/08/2017 40,000 19,305 59,305 (92) 59,213 (92) 59,212	Euro Group €'000							€'000	€'000				
Pronovisis   03/10/2017   20,000	Accountor	10/12/2015	10,000	8,661	18,661	(15)	18,646	(15)	18,646	_	8,646	3.22%	1.9x
PCOM   18/12/2017   10,000   4,955   14,955   (19)   14,936   (19)   14,936   -     4,936   16,60%   1.5	Lima	11/08/2017	40,000	19,305	59,305	(92)	59,213	(92)	59,212	_	19,213	13.05%	1.5x
Vyaire   16/04/2018   6,000   1,134   7,134   (1,100)   6,034   (1,100)   6,034   902   936   11,79%   1.0	Pronovias	03/10/2017	20,000	1,032	21,032	(8,703)	12,329	(8,703)	12,329	5,161	(2,510)	8.53%	0.6x
Lima Add on 18/06/2020 2,353 286 2,639 (4) 2,635 (4) 2,635 — 282 13.41% 1.1	IPCOM	18/12/2017	10,000	4,955	14,955	(19)	14,936	(19)	14,936	_	4,936	16.60%	1.5x
Sep Group From   Sep Say	Vyaire	16/04/2018	6,000	1,134	7,134	(1,100)	6,034	(1,100)	6,034	902	936	11.79%	1.0x
Comp	Lima Add on	18/06/2020	2,353	286	2,639	(4)	2,635	(4)	2,635	_	282	13.41%	1.1x
Sunrise   16/04/2018   27,901   -   27,901   (45)   27,856   (52)   32,371   7,158   7,113   8,21%   1.0			88,353	35,372	123,725	(9,933)	113,792	(9,933)	113,792	6,064	31,503	11.10%	1.3x
27,901   - 27,901   (45) 27,856   (52) 32,371   7,158   7,113   8.21%   1.0	GBP Group £'000							€'000	€'000				
Substitution   Sub	Sunrise	16/04/2018	27,901	_	27,901	(45)	27,856	(52)	32,371	7,158	7,113	8.21%	1.0x
MSX   06/01/2017   6,946   7,192   14,138   (39)   14,099   (34)   12,176   3,697   10,850   10.89%   2.00			27,901	_	27,901	(45)	27,856	(52)	32,371	7,158	7,113	8.21%	1.0x
Centrient         31/10/2018         17,352         —         17,352         (424)         16,928         (366)         14,620         5,132         4,708         10,25%         1.0           Total Portfolio Loans           Total Portfolio Loans (Less ECL)         183,344           Total Portfolio Loans (Less ECL)         172,959         10.34%         1.2           **Calculated as C multiplied by the FX Closing Rate at 30.06.21 minus F           AVAILABLE FOR SALE EQUITY           Date Of Investment         Cost         Valuation adjustment         3009,2021         € equivalent         Gross         Mo           Sunrise Medical         29/07/2015         2,513         13,887         16,400         16,400         0.00%         6.5           Autoform         15/12/2016         2,171         9,839         12,010         12,010         -0.45%         5.5           Audiotonix         22/06/2017         298         326         624         624         41.05%         2.1           Audiotonix         22/06/2017         298         326         624         624         41.05%         2.5	USD Group \$'000							€'000	€'000				
Total Portfolio Loans	MSX	06/01/2017	6,946	7,192	14,138	(39)	14,099	(34)	12,176	3,697	10,850	10.89%	2.0x
Total Portfolio Loans  Total Portfolio Loans (Less ECL)  Total Portfolio Loans (Less ECL)  *Calculated as C multiplied by the FX Closing Rate at 30.06.21 minus F  AVAILABLE FOR SALE EQUITY  Date Of Investment Cost adjustment 30.09.2021  Sunrise  Medical 29/07/2015 2,513 13,887 16,400  Autoform 15/12/2016 2,171 9,839 12,010  Audiotonix 22/06/2017 298 326 624  4,981 24,053 29,034  183,344  1.2  Equivalent Gross Moleculary  Fequivalent Gross Moleculary  16,400  16,400  0.00% 6.5  5.8  4,981 24,053 29,034  29,034  29,034  29,034  29,034  20,034  2	Centrient	31/10/2018	17,352	_	17,352	(424)	16,928	(366)	14,620	5,132	4,708	10.25%	1.0x
Total Portfolio Loans (Less ECL)  *Calculated as C multiplied by the FX Closing Rate at 30.06.21 minus F  AVAILABLE FOR SALE EQUITY  Date Of Investment Cost adjustment 30.09.2021  Sunrise Medical 29/07/2015 2,513 13,887 16,400  Autoform 15/12/2016 2,171 9,839 12,010  Audiotonix 22/06/2017 298 326 624  4,981 24,053 29,034  (10,385)  Revaluation of equity at 30.09.2021  Feequivalent € equivalent € equivalent € equivalent € equivalent € exclision of equity at 30.09.2021  Feeduivalent € equivalent € equivalent € exclision of equity at 40.000 0.00% 6.500 0			24,298	7,192	31,490	(463)	31,027	(400)	26,796	8,829	15,558	10.45%	1.3x
Total FCL Impairment (10,385)  Total Portfolio Loans (Less ECL) 172,959 10.34% 1.2  *Calculated as C multiplied by the FX Closing Rate at 30.06.21 minus F  AVAILABLE FOR SALE EQUITY  Date Of Investment Cost adjustment 30.09.2021 € equivalent (Excl. EC)  Sunrise  Medical 29/07/2015 2,513 13,887 16,400 16,400 0.00% 6.5  Autoform 15/12/2016 2,171 9,839 12,010 12,010 -0.45% 5.5  Audiotonix 22/06/2017 298 326 624 624 624 41.05% 2.1  4,981 24,053 29,034 29,034 29,034 2.26% 5.8													
Total Portfolio Loans (Less ECL)  *Calculated as C multiplied by the FX Closing Rate at 30.06.21 minus F  AVAILABLE FOR SALE EQUITY  Date Of Investment Cost adjustment 30.09.2021  Sunrise Medical 29/07/2015 2,513 13,887 16,400  Autoform 15/12/2016 2,171 9,839 12,010  Audiotonix 22/06/2017 298 326 624  4,981 24,053 29,034  172,959  10.34% 1.2  Revaluation of equity at € equivalent € equivalen	Total Portfolio	Loans							183,344				
*Calculated as C multiplied by the FX Closing Rate at 30.06.21 minus F  AVAILABLE FOR SALE EQUITY  Date Of Investment Cost Valuation of equity at 30.09.2021  Sunrise Medical 29/07/2015 2,513 13,887 16,400  Autoform 15/12/2016 2,171 9,839 12,010  Audiotonix 22/06/2017 298 326 624  4,981 24,053 29,034  Equivalent © equivalent © Gross Mo (Excl. EC)  16,400  16,400  16,400  12,010  12,010  12,010  12,010  20,45% 5.8	Total ECL Impa	airment						(10,385)					
*Calculated as C multiplied by the FX Closing Rate at 30.06.21 minus F  AVAILABLE FOR SALE EQUITY  Date Of Investment Cost Valuation of equity at 30.09.2021  Sunrise Medical 29/07/2015 2,513 13,887 16,400  Autoform 15/12/2016 2,171 9,839 12,010  Audiotonix 22/06/2017 298 326 624  4,981 24,053 29,034  Equivalent © equivalent © Gross Mo (Excl. EC)  16,400  16,400  16,400  12,010  12,010  12,010  12,010  20,45% 5.8	Total Portfolio	Loans (Less F	CI.)						172,959			10.34%	1.2x
SALE EQUITY         Date Of Investment         Valuation of equity at 30.09.2021         Revaluation of equity at 30.09.2021         € equivalent €'000         Gross Mo IRR         Gross Mo IRR         Modical Excl. EC           Sunrise Medical         29/07/2015         2,513         13,887         16,400         16,400         0.00%         6.5           Autoform         15/12/2016         2,171         9,839         12,010         12,010         -0.45%         5.5           Audiotonix         22/06/2017         298         326         624         624         41.05%         2.1           4,981         24,053         29,034         29,034         29,034         2.26%         5.8				0.06.21 minus F	=				, -				
SALE EQUITY         Date Of Investment         Valuation of equity at 30.09.2021         Revaluation of equity at 30.09.2021         € equivalent €'000         Gross Mo IRR         Gross Mo IRR         Modical Excl. EC           Sunrise Medical         29/07/2015         2,513         13,887         16,400         16,400         0.00%         6.5           Autoform         15/12/2016         2,171         9,839         12,010         12,010         -0.45%         5.5           Audiotonix         22/06/2017         298         326         624         624         41.05%         2.1           4,981         24,053         29,034         29,034         29,034         2.26%         5.8	AVAILABLE FOR												
Medical       29/07/2015       2,513       13,887       16,400       16,400       0.00%       6.5         Autoform       15/12/2016       2,171       9,839       12,010       12,010       -0.45%       5.5         Audiotonix       22/06/2017       298       326       624       624       41.05%       2.1         4,981       24,053       29,034       29,034       29,034       2.26%       5.8	SALE EQUITY		Cost		of equity at								Gross MoM (Excl. ECL)
Autoform       15/12/2016       2,171       9,839       12,010       12,010       -0.45%       5.5         Audiotonix       22/06/2017       298       326       624       624       41.05%       2.1         4,981       24,053       29,034       29,034       29,034       2.26%       5.8		20/07/2015	2 512	12 007	16.400				16.400			0.00%	6.5x
Audiotonix 22/06/2017 298 326 624 624 41.05% 2.1 4,981 24,053 29,034 29,034 29,034 2.26% 5.8			,	,	,				,				5.5x
4,981 24,053 29,034 29,034 2.26% 5.8													2.1x
	AUUIOIOIIX	22/00/201/											5.8x
Total Portfolio Value 201,993 2.26% 5.8			,	,	,				,				
	Total Portfolio	Value							201,993			2.26%	5.8x

# Notes to the Management Accounts For the period ended 30 September 2021

#### 2. Realised Asset Summary

All source currency		А	В	С	D=(A-B+C)		
	Date Of	Investment at Cost	Realised Amount incl.	Cash interest received ITD	Value Creation		Gross MoM
Partially and fully exited assets	Investment	(source ccy)	PIK (source ccy)	(source ccy)	(source ccy)	Gross IRR	(Excl. ECL)
EUR Group €'000							
Securitas Direct Mezzanine	02/03/2012	35,914	(51,427)	_	15,513	14.8%	1.4 x
Unilabs Mezzanine	18/04/2012	10,000	(12,135)	_	2,135	18.6%	1.2 x
BSN Equity	21/08/2012	3,750	(7,452)	_	3,702	15.9%	2.0 x
BSN Medical II	28/08/2012	38,001	(50,105)	_	12,104	14.9%	1.3 x
Unilabs PIK	17/07/2013	29,437	(43,610)	_	14,173	13.3%	1.5 x
Icopal	09/05/2014	9,823	(12,608)	_	2,785	15.3%	1.3 x
Megadyne	25/07/2014	17,831	(25,117)	_	7,286	11.9%	1.4 x
Megadyne Mezz	28/07/2014	16,769	(25,904)	_	9,135	11.4%	1.5 x
Megadyne Equity	28/08/2014	8,650	(22,088)	_	13,438	26.1%	2.6 x
Quironsalud	03/12/2014	20,000	(24,117)	3,621	7,738	10.0%	1.2 x
Sebia Equity	10/12/2014	5,033	(10,014)	-	4,981	25.0%	2.0 x
Sebia Equity	17/12/2014	10,000	(12,031)	1,731	3,762	10.5%	1.2 x
Metrologic	28/04/2015	13,750	(16,803)	-	3,053	10.4%	1.2 x
Sunrise Equity	29/07/2015	3,333	(3,333)	_	-	0.0%	1.0 x
Sunrise	30/07/2015	58,200	(68,735)	11,317	21,852	10.3%	1.0 x
Automic	28/09/2015	28,667	(34,164)	-	5,497	15.1%	1.2 x
Securitas Direct PUN	21/10/2015	50,300	(61,157)	7,017	17,874	13.5%	1.2 x
P&I Second Lien	28/01/2016	6,250	(6,898)	2,261	2,909	14.1%	1.1 x
P&I PIK	28/01/2016	6,250	(8,275)	2,201	2,025	44.3%	1.3 x
Autoform	22/07/2016	36,000	(40,653)	3,303	7,956	13.4%	1.1 x
Unilabs New Notes	10/10/2016	53,105	(56,239)	3,455	6,589	10.6%	1.1 x
P&I II	10/11/2016	7,368	(7,990)	-	622	15.4%	1.1 x
P&I II	10/11/2016	10,132	(11,812)	_	1,680	12.0%	1.2 x
IFS .	26/05/2017	9,904	(10,355)	_	451	25.2%	1.0 x
Sebia	19/01/2018	10,000	(11,000)	_	1,000	9.97%	1.1 x
Nets	06/02/2018	22,000	(24,227)	1,335	3,562	14.6%	1.1 x
Audiotonix Equity (Partially exited)	21/04/2020	1,191	(4,290)	- 1,000	3,099	41.1%	1.2 x
IFS	24/09/2020	30,000	(42,184)	_	12,184	11.8%	1.2 x
Altus Intervention (Equity)	14/09/2020	6,475	(+2,10+)	_	(6,475)	0.0%	0.0 x
Autoform Equity (Partial exited – Return of Capital)		1,333	(1,333)	_	(0,470)	0.0%	0.0 x
Autorom Equity (Furtial exited Protein or Suprial)	01/00/2021	559,466	(706,056)	34.040	180,630	0.070	σ.σ.χ
		007,400	(700,000)	04,040	100,000		
GBP Group £'000							
PHS - Second Lien	23/03/2012	3,000	(1,323)	315	(1,362)	-46.3%	0.4 x
					, ,	17.5%	1.3 x
Wood Mackenzie	02/08/2012	37,882	(49,845)	_	11,963		
Wood Mackenzie Corialis	02/08/2012 05/11/2014		(49,845) (24,704)		9,238	12.3%	
Corialis	05/11/2014	19,524	(24,704)	4,058	9,238	12.3%	1.3 x
		19,524 11,542	(24,704) (14,429)	4,058 2,308			1.3 x 1.3 x
Corialis Host Europe	05/11/2014 24/02/2015	19,524 11,542 31,500	(24,704) (14,429) (35,690)	4,058	9,238 5,195	12.3% 12.8%	1.3 x 1.3 x 1.1 x
Corialis Host Europe LGC Science IVC	05/11/2014 24/02/2015 08/03/2016	19,524 11,542	(24,704) (14,429) (35,690) (48,280)	4,058 2,308 3,402	9,238 5,195 7,592	12.3% 12.8% 11.7%	1.3 x 1.3 x 1.1 x 1.4 x
Corialis Host Europe LGC Science	05/11/2014 24/02/2015 08/03/2016 30/01/2017	19,524 11,542 31,500 37,500 1,422	(24,704) (14,429) (35,690) (48,280) (2,563)	4,058 2,308 3,402	9,238 5,195 7,592 10,780	12.3% 12.8% 11.7% 14.0%	1.3 x 1.3 x 1.1 x 1.4 x 1.7 x
Corialis Host Europe LGC Science IVC IVC Equity (Partially exited)	05/11/2014 24/02/2015 08/03/2016 30/01/2017 31/01/2017	19,524 11,542 31,500 37,500 1,422 3,750	(24,704) (14,429) (35,690) (48,280) (2,563) (4,271)	4,058 2,308 3,402 - -	9,238 5,195 7,592 10,780 1,141	12.3% 12.8% 11.7% 14.0% 24.8%	1.3 x 1.3 x 1.1 x 1.4 x 1.7 x 1.1 x
Corialis Host Europe LGC Science IVC IVC Equity (Partially exited) Audiotonix IVC II	05/11/2014 24/02/2015 08/03/2016 30/01/2017 31/01/2017 30/03/2017 27/07/2017	19,524 11,542 31,500 37,500 1,422 3,750 1,850	(24,704) (14,429) (35,690) (48,280) (2,563) (4,271) (2,271)	4,058 2,308 3,402 - -	9,238 5,195 7,592 10,780 1,141 924 421	12.3% 12.8% 11.7% 14.0% 24.8% 12.0% 11.6%	1.3 x 1.3 x 1.1 x 1.4 x 1.7 x 1.1 x 1.3 x
Corialis Host Europe LGC Science IVC IVC Equity (Partially exited) Audiotonix IVC II LGC Equity	05/11/2014 24/02/2015 08/03/2016 30/01/2017 31/01/2017 30/03/2017 27/07/2017 21/04/2020	19,524 11,542 31,500 37,500 1,422 3,750 1,850 5,887	(24,704) (14,429) (35,690) (48,280) (2,563) (4,271) (2,271) (17,931)	4,058 2,308 3,402 - -	9,238 5,195 7,592 10,780 1,141 924 421 12,044	12.3% 12.8% 11.7% 14.0% 24.8% 12.0% 11.6% 31.0%	1.3 x 1.3 x 1.1 x 1.4 x 1.7 x 1.1 x 1.3 x 3.0 x
Corialis Host Europe LGC Science IVC IVC Equity (Partially exited) Audiotonix IVC II LGC Equity Altus Intervention	05/11/2014 24/02/2015 08/03/2016 30/01/2017 31/01/2017 30/03/2017 27/07/2017 21/04/2020 14/09/2020	19,524 11,542 31,500 37,500 1,422 3,750 1,850 5,887 27,500	(24,704) (14,429) (35,690) (48,280) (2,563) (4,271) (2,271) (17,931) (770)	4,058 2,308 3,402 - - 403 -	9,238 5,195 7,592 10,780 1,141 924 421 12,044 (26,730)	12.3% 12.8% 11.7% 14.0% 24.8% 12.0% 11.6% 31.0%	1.3 x 1.3 x 1.1 x 1.4 x 1.7 x 1.1 x 1.3 x 3.0 x 0.6 x
Corialis Host Europe LGC Science IVC IVC Equity (Partially exited) Audiotonix IVC II LGC Equity Altus Intervention Corialis	05/11/2014 24/02/2015 08/03/2016 30/01/2017 31/01/2017 30/03/2017 27/07/2017 21/04/2020 14/09/2020 30/10/2020	19,524 11,542 31,500 37,500 1,422 3,750 1,850 5,887 27,500 10,787	(24,704) (14,429) (35,690) (48,280) (2,563) (4,271) (2,271) (17,931) (770) (10,787)	4,058 2,308 3,402 - -	9,238 5,195 7,592 10,780 1,141 924 421 12,044 (26,730) 5,868	12.3% 12.8% 11.7% 14.0% 24.8% 12.0% 11.6% 31.0% -37.2% 10.4%	1.3 x 1.3 x 1.1 x 1.4 x 1.7 x 1.1 x 1.3 x 3.0 x 0.6 x 1.3 x
Corialis Host Europe LGC Science IVC IVC Equity (Partially exited) Audiotonix IVC II LGC Equity Altus Intervention	05/11/2014 24/02/2015 08/03/2016 30/01/2017 31/01/2017 30/03/2017 27/07/2017 21/04/2020 14/09/2020	19,524 11,542 31,500 37,500 1,422 3,750 1,850 5,887 27,500	(24,704) (14,429) (35,690) (48,280) (2,563) (4,271) (2,271) (17,931) (770)	4,058 2,308 3,402 - - 403 -	9,238 5,195 7,592 10,780 1,141 924 421 12,044 (26,730)	12.3% 12.8% 11.7% 14.0% 24.8% 12.0% 11.6% 31.0%	1.3 x 1.3 x 1.1 x 1.4 x 1.7 x 1.1 x 1.3 x 3.0 x 0.6 x

#### Notes to the Management Accounts

For the period ended 30 September 2021

#### 2. Realised Asset Summary (continued)

All source currency		А	В	С	D=(A-B+C)		
Partially and fully exited assets USD Group \$'000	Date Of Investment	Investment at Cost (source ccy)	Realised Amount incl. PIK (source ccy)	Cash interest received ITD (source ccy)	Value Creation (source ccy)	Gross IRR	Gross MoM (Excl. ECL)
	00/05/0010	7.000	(4.0.457)		2.227	16.00	
Diana PIK	28/06/2012	7,620	(10,457)	_	2,837	16.9%	1.4 x
Ammeraal	15/07/2015	11,087	(14,417)	3,164	6,495	10.3%	1.3 x
MSXi (Partially exited)	06/01/2017	19,703	(20,648)	_	945	16.4%	1.4 x
Audiotonix	30/03/2017	13,760	(15,661)	1,672	3,573	12.0%	1.1 x
Teamviewer	05/04/2017	10,000	(10,000)	2,583	2,583	12.7%	1.3 x
Acuris	12/09/2017	25,000	(25,000)	4,278	4,278	10.5%	1.2 x
TBS	16/04/2018	26,046	(29,486)	2,299	5,739	16.3%	1.1 x
Itiviti Second Lien	20/05/2021	36,000	(36,000)	11,147	11,147	11.4%	1.3 x
Itiviti (Preferred Equity)	20/05/2021	9,000	(13,383)	_	4,383	14.5%	1.5 x
ADB Safegate	25/08/2021	48,000	(48,000)	16,124	16,124	8.4%	1.3 x
		206,216	(223,053)	41,267	58,104		

#### 3. Trade Creditors & Other Payables

€′000	Unaudited Q3 2021	Unaudited Q2 2021	Unaudited Q1 2021	Audited 2020
Trade creditors	(7)	(1,790)	(278)	(126)
Accruals	(155)	(93)	(52)	(117)
	(162)	(1,883)	(330)	(243)

The large trade creditor balance at Q2 2021 was in relation to accrued Q1 and Q2 2021 Profit Share which was settled during Q3 2021.

#### 4. NAV Movement

€′000	Unaudited Q3 2021	Unaudited Q2 2021	Unaudited Q1 2021	Audited 2020
Opening NAV	222,728	293,380	282,537	371,436
Capital Contributions	2,939	-	_	4,120
Distributions	(46,737)	(62,950)	(2,710)	(86,477)
Profit share	(689)	(911)	(863)	(4,577)
Share of current period gain/(loss)	(809)	(4,165)	6,328	13,945
Foreign exchange movement	873	(2,626)	8,088	(15,910)
Closing NAV	178,305	222,728	293,380	282,537

#### Notes to the Management Accounts

For the period ended 30 September 2021

#### 5. Realised and Unrealised Gains/Losses on Investments

Unrealised €'000	Value B/F 1.1.2021	Repayment	Addition	Write off	FX YTD	Unrealised movement YTD	Release of unrealised on Repayments	Investment Value at Q3 2021
Autoform Equity	12,680	(1,333)	_	_	_	663	_	12,010
Audiotonix Equity	645	_	_	_	_	(21)	_	624
IVC Equity	9,233	(3,313)	_	_	308	_	(6,228)	_
Sunrise Equity	16,200	_	_	_	-	200	_	16,400
Total	38,758	(4,646)	-	-	308	842	(6,228)	29,034

Realised £'000	Cost (source ccy)	Realised gain/(loss) on disposal (source ccy)	Proceeds (source ccy)	Cost (EUR equivalent)	Realised gain/ (loss) on disposal (EUR equivalent)	Proceeds (EUR equivalent)
IVC Equity ADB	2,863 48,000	20,939 (5,058)	23,802 42,942	3,313 39,689	24,232 (4,309)	27,545 35,380
Total	50,863	15,881	66,744	43,002	19,923	32,428

During the period ADB was fully divested.

#### 6. ECL Loss Allowance

Total ECL			10,385	9,990	10,757	10,381
Stage 1 Assets	A-B		217	365	284	275
Stage 2 Assets	С		365	_	1,023	1,006
Pronovias	С	40% Principal	8,703	8,525	8,350	8,000
Vyaire	D	15% Principal plus PIK	1,100	1,100	1,100	1,100
€'000	Category	% of Provision	Provision @ Q3 2021	Provision @ Q2 2021	Provision @ Q1 2021	Provision @ Q4 2020
ASSET						

#### **ECL Quarterly Allowance**

€'000	Q3 2021	02 2021	01 2021	Q4 2020
Opening Balance	9,990	10,757	10,381	10,030
Increase/(decrease) in provision	395	(754)	329	360
Foreign exchange movement	_	(13)	47	(9)
Closing Balance	10,385	9,990	10,757	10,381

The ECL allowance in Q3 2021 totalled €10,385,129 up €395,520 from the ECL allowance of €9,989,609 recorded in Q2 2021. The increase in the ECL allowance is attributed to:

Stage 1 assets: decrease of €147,365 Stage 2 assets: increase of €365,332 Stage 3 assets: increase of €177,553

The overall increase of €395,520, reflects the change from Centrient from Stage 1 to Stage 2 as at 30 September 2021.

#### Notes to the Management Accounts

For the period ended 30 September 2021

#### 7. Taxation

Any tax liability arising on the activity of the Fund will be borne by the individual Partners and not the Fund itself.

The provision for taxation is made in relation to the wholly owned subsidiary MezzVest Luxembourg III, S.à r.l., which is subject to corporation tax in Luxembourg.

Provisions for taxation payable in Luxembourg correspond to the difference between the estimated provisions created by the Fund and the advance payments, which are notified by the Luxembourg tax authorities, for the financial year.

#### 8. Priority profit share

Prior to any distributions to the Limited Partners, the Partnership will pay to the General Partner a per annum Priority Profit Share, calculated as 1.5% of aggregate commitments until the expiration of the call period on 31 July 2018, after which the Priority Profit Share will be calculated on a Reduced Acquisition Cost, as per the LPA.

The amount recognised year to date in relation to priority profit share as at 30 September 2021 was €2,463,375.

#### 9. Carried interest

Carried interest expense is recognised in the Consolidated Statement of Comprehensive Income on an accruals basis when the calculation indicates that the preferred return of 8% would have been achieved and distribution arrangements have been met were the Partnership's investments realised at their fair values.

Carried interest is measured at amortised cost and calculated based on the fair value of the investments of the Partnership as measured at the reporting date. Carried interest is equal to the Carried Interest Partner's hypothetical share of profits, taking into account the cash already distributed (where applicable) from the Partnership and amount of divestment proceeds receivable. Therefore, based on the calculation described above, the Partnership recognises a financial liability based on the estimated fair value of its assets at the balance sheet date. Carried interest is paid when the particular payment distribution arrangements as set out above and in the LPA are met.

#### 10. Cash

As at 30 September 2021, the cash balance on account was €22,719,144, of which £13,125,000 is in relation to the repayment from Exclusive Networks, which will be distributed post quarter end. The remaining funds are held on account in relation to Lima.

#### 11. Foreign Exchange Movement

For the period to 30 September 2021, the foreign exchange movement was  $\le$ 6,335,112. This is composed of foreign exchange movements on financial assets amounting to  $\le$ 6,104,242 (gain). The residual amount of  $\le$ 230,870 (gain) is mainly composed of the retranslation of the bank balance and the FX impact on P&L items, as well as movements on the foreign exchange revaluation reserve.

The below table summarises the fluctuation of foreign currencies against the EUR from 1 January 2021 to 30 September 2021.

	Char	nge in currency rate
rrency	% change to EUR 2021	% change to EUR 2020
	4.47%	-5.46%
	5.98%	-8.50%

#### 12. Disclaimer

The preliminary unaudited management accounts are prepared by MV Credit Partners LLP and MV Credit S.à r.l. (together "MV Credit"), and are for informational purposes only. These accounts are based on available information, certain assumptions and estimates that MV Credit believe to be reasonable and factually supportable. These accounts are subject to future adjustment at any time, and should not be deemed to fully represent the financial condition of MezzVest III, L.P. The information presented in these accounts of MezzVest III, L.P.

#### Appendix to the Consolidated Financial Statements (Unaudited)

For the period ended 30 September 2021

#### US GAAP Reconciliation

The Partnership prepares its consolidated financial statements in accordance with the International Financial Reporting Standards ("IFRS") as adopted by the European Union. The Partnership has presented the following reconciliation of profit after tax and of Partners' capital under US GAAP to meet the requirements of certain investors.

In June 2009, the Financial Accounting Standards Board ("FASB") issued the FASB Accounting Standards Codification ("ASC"). The ASC has become the single source of non-governmental generally accepted accounting principles in the United States ("GAAP") recognised by the FASB in the preparation of financial statements. The rules and interpretative releases of the Securities and Exchange Commission are additional sources of GAAP for the General Partner. The General Partner has prepared the following reconciliation between the financial statements prepared in accordance with IFRS and US GAAP.

The principal accounting policies which have been applied for the purposes of preparing the US GAAP reconciliation relate to the valuation of investments, recognition of carried interest and the recognition of tax balances. A reconciliation of profit after tax and of partners' capital under US GAAP have been presented to highlight the differences between IFRS and US GAAP.

Under ASC 205-30, the liquidation basis of preparation is not applied unless liquidation is imminent. The Partnership does not meet the criteria for implementing the liquidation basis of accounting in accordance with US GAAP. There is no change in the presentation of the financial statements from the presentation of the financial statements on a going concern basis under IFRS.

The tax recognised within the consolidated financial statements relate to the subsidiary, MezzVest Luxembourg III, S.à r.I. The Partnership is subject to ASC 740 "Income Taxes" ("ASC 740"), which established for all entities, including pass-through entities, a minimum threshold for financial statement recognition of positions taken in filing a tax return (including whether an entity is taxable in a particular jurisdiction), and requires certain expanded tax disclosure.

The General Partner has assessed the facts, circumstances and information available at the reporting date, and has not identified any significant uncertain tax positions, at the date of approval of these financial statements as prescribed by ASC 740.

For the period ended 30 September 2021 a reconciliation of the profit after tax is shown below:

Profit/(loss) after tax for the period under US GAAP	35,012	(40,827)
CECL - ECL Lifetime Provision	(343)	(11,319)
IFRS 9 - Effective Interest Calculation Method	176	510
IFRS 9 - ECL Provision Adjustment	395	2,160
Carried Interest Provision Adjustment	29,558	(25,636)
Adjustments		_
Profit/(loss) after tax for the period under IFRS	5,226	(6,543)
€′000	YTD 2021	FY 2020

For the financial year ended 30 September 2021 a reconciliation of total Partners' Capital is shown below:

Total Partners' Capital under US GAAP	225,794	300,631
CECL - ECL Lifetime Provision	(11,662)	(11,319)
IFRS 9 - Effective Interest Calculation Method	686	510
IFRS 9 - ECL Provision Adjustment	10,385	10,381
Carried Interest Provision Adjustment	48,080	18,522
Adjustments		-
Total Partners' Capital under IFRS	178,305	282,536
€′000	YTD 2021	FY 2020

#### Individual Investment Summary – TransGlobe Life Insurance Inc

For the Period Ended 30 September 2021

Investor name	TransGlobe Life Insurance Inc
Investor commitment %	1.71
Investor GP PPS	
Commitment %	1.73
Currency Election	EUR
Commitment	10,000,000
Undrawn Commitment	822,378

EUR Consolidated Capital Account - Inception to Date

	Opening NAV	Capital Called	Recalled Distributions	Distributions	Profit & Loss	Realised Gain / (Loss)	Unrealised Gain / (Loss)	Unrealised FX Gain/(Loss)	Profit Share Attributable to the GP	Carried Interest (unrealised)	Net Gain / (Loss)	NAV @ Reporting Date
TransGlobe Life Insurance Inc	-	9,177,622	318,782	(9,795,931)	4,480,017	124,268	486,705	(89,970)	(831,131)	(831,012)	3,338,877	3,039,350
TOTAL MezzVest III, LP	-	536,343,473	18,632,268	(572,796,170)	261,849,201	7,263,243	28,447,052	(5,258,606)	(48,095,679)	(48,080,063)	196,125,148	178,304,719

Currency Capital Accounts – Year to Date

	Opening NAV	Capital Called	Recalled Distributions	Distributions	Profit & Loss	Realised Gain / (Loss)	Unrealised Gain / (Loss)	Unrealised FX Gain/(Loss)	Profit Share Attributable to the GP	Carried Interest (unrealised)	Net Gain / (Loss)	NAV @ Reporting Date
EUR	2,040,411	50,281	-	(50,281)	188,098	-	14,394	-	(42,577)	(510,876)	(350,961)	1,689,450
GBP	855,715	-	-	(414,272)	17,047	358,245	(93,023)	-	-	-	282,269	723,712
USD	2,252,997	-	-	(1,665,364)	88,145	(86,531)	-	-	-	-	1,614	589,247
TOTAL EUR Consolidated	4,828,265	50,281	-	(1,923,013)	280,181	340,855	(92,154)	108,388	(42,577)	(510,876)	83,817	3,039,350
TOTAL MezzVest III, LP	282,536,506	2,938,824	-	(112,396,727)	16,376,094	19,922,406	(5,386,269)	6,335,112	(2,463,373)	(29,557,854)	5,226,116	178,304,719

There may be small rounding differences in the above tables